viewInvion Ltd

Invion's strategic alliance with Cho Group provides distribution opportunities

The group's strategic objective is to identify and in-license novel drug assets.

Picture of the capsules
Invion is exclusive distributor and licensee of the Photosoft technology in Australia and NZ

Invion Ltd (ASX:IVX) largely focused on the company's strategy for the upcoming 12 months in delivering its full-year result for the 12 months to December 31, 2017.

This forward-looking approach appeared to resonate with investors as the company's shares increased 20% to $0.12.

Invion’s overarching strategic objective for the group has been to identify and in-license novel drug assets.

By mitigating risks along each programs clinical development pathway, Invion aims to enhance the value of these assets, ultimately realising their commercial potential.

Strategic alliance with Cho Group

In keeping with its strategy, Invion has entered into a strategic alliance with The Cho Group Limited.

This provides the company with an opportunity to expand its business and develop its asset pipeline through the identification and in-licensing of new advanced clinical initiatives.

Through this process, Invion identified Photosoft, a proprietary photodynamic therapy targeted at the treatment of cancers.

Invion appointed exclusive distributor and licensee

The Cho Group agreed to appoint Invion as exclusive distributor and licensee of the Photosoft technology in Australia and New Zealand for the treatment of cancers.

Invion was engaged to conduct the clinical development of Photosoft globally, initially targeting prostate cancer in Australian-run clinical trials.

Subsequent to those developments, Invion has been working to determine the potential timing and costs of phase II and phase III clinical trials in prostate cancer.

Other applications for Photosoft

Invion is also exploring opportunities for the treatment of skin cancers and other disorders.

The company is aiming to develop a strategy to target ovarian cancer as a future clinical opportunity for Photosoft.

Invion is looking to progress its early stage development of a treatment which addresses the underlying cause of chronic airway diseases including asthma and chronic obstructive pulmonary disease.

Quick facts: Invion Ltd

Price: 0.01 AUD

Market: ASX
Market Cap: $55.01 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Full interview: Alkane Resources hits almost 700 metres of mineralisation in...

Alkane Resources Ltd (ASX:ALK) managing director Nic Earner updates Proactive on follow-up drill results from the Boda prospect within the wider Northern Molong Porphyry Project (NMPP) near Orange in New South Wales. The drilling is part of a 5,000-metre diamond core drilling exploration...

5 hours, 54 minutes ago

2 min read